H A R E S I G N

Primary care management consulting for GP practices and PCNs across England. IGPM Accredited Member.

Contact Info
Connect

LinkedIn

Primary care consulting for GP practices & PCNs across England. Get in touch →

MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) (Crescent Pharma Limited livery)

Published
8 June 2026
Source
PSNC Dispensing & Supply News
Imported
8 Jun 2026

MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) Drug alert number: EL(26)A/28 Date issued: 08 June 2026 Cadila Pharmaceuticals Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of a batch of Mirtazapine 30mg Film-Coated Tablets distributed in Crescent Pharma Limited livery. DMRC [...]

The post MHRA Class 4 Medicines Defect Notification: Mirtazapine 30mg Tablets (Cadila Pharmaceuticals) (Crescent Pharma Limited livery) appeared first on Community Pharmacy England.

View Original Alert
Important: This alert is aggregated automatically for information only. Always refer to the original source and follow your practice's own clinical governance procedures.
Get the weekly digest — all new alerts summarised and delivered to your NHS inbox every Monday.
View this week's digest

Back to Safety Alerts

Unlock your Practice Performance Overview

Register your practice for free to bring QOF, workforce, access, finance, contract and CQC data into a single live dashboard — benchmarked to national figures with an at-a-glance health score.